stockrowInsulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
Follow PODD
Alert me
Insulet Corporation (PODD) Return on equity
Insulet Corporation's return on equity over the twelve months to 30 September 2026 was 28.9%, up 10.8 percentage points from fiscal 2025 (18.1%). Over the past ten years it has ranged from −124.7% (fiscal 2015) to 43.0% (fiscal 2024); the current reading is higher than 82% of that period. That is above the Medical Devices industry median of −10.4% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 18.1% | (24.91) |
| FY2024 | 43.0% | 8.91 |
| FY2023 | 34.1% | 33.23 |
| FY2022 | 0.89% | (2.01) |
| FY2021 | 2.90% | 0.90 |
| FY2020 | 2.00% | (6.06) |
| FY2019 | 8.06% | 6.28 |
| FY2018 | 1.78% | 25.96 |
| FY2017 | −24.2% | 35.24 |
| FY2016 | −59.4% | 65.32 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PODD Insulet Corporation | 28.9% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 14.3% |
| BIO Bio-Rad Laboratories, Inc. compare | 14.3% |
| GMED Globus Medical, Inc. compare | 12.1% |
| PEN Penumbra, Inc. compare | 10.7% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| BRKR Bruker Corporation compare | −7.04% |
| TXG 10x Genomics compare | −9.40% |
| GKOS Glaukos Corporation compare | −22.8% |
| Medical Devices industry median | −10.4% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement